ArticleAmerican journal of translational research2026
Predictive value of immunohistochemical parameters combined with clinicopathological features in predicting recurrence after lymph node resection in endometrial cancer patients.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the predictive value of immunohistochemical markers combined with clinicopathological parameters for recurrence after lymph node dissection in patients with endometrial cancer (EC) and to construct a comprehensive risk assessment model.
methodsA retrospective study was conducted on 118 EC patients who underwent radical surgery with systematic lymph node dissection between January 2023 and December 2025. Clinicopathological characteristics and expression of estrogen receptor (ER), progesterone receptor (PR), p53, and Ki-67 were collected. Kaplan-Meier (KM) analysis, Log-rank test, and Cox proportional hazards regression (Cox regression) models were used to identify prognostic factors. Receiver operating characteristic (ROC) curves and the DeLong test were applied to assess predictive performance.
resultsDuring a median follow-up of 26 months, 28 patients (23.7%) experienced recurrence. Univariate analysis showed that advanced International Federation of Gynecology and Obstetrics stage (FIGO stage), poor differentiation, deep myometrial invasion, positive lymphovascular space invasion (LVSI), lymph node metastasis, aberrant p53 expression, and high Ki-67 expression were significantly associated with recurrence (all P<0.05). Multivariate analysis identified lymph node metastasis (P = 0.005), aberrant p53 expression (P = 0.008), Ki-67 ≥30% (P = 0.022), and LVSI positivity (P = 0.042) as independent risk factors. The combined model achieved an area under the curve (AUC) of 0.876 (95% confidence interval (CI): 0.807-0.945), with a sensitivity of 85.7% and specificity of 82.2%, outperforming individual predictors (all P<0.05).
conclusionKey clinicopathological and immunohistochemical factors are independently associated with recurrence after lymph node dissection in EC. The model may improve risk stratification and support postoperative follow-up and risk management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.